Lexicon Pharmaceuticals, Inc.

NASDAQ:LXRX

Biotechnology

Healthcare
$1.72 -2.64%

-$0.05 today

Market cap
$765.80M
Beta
1.07
P/E (TTM)
-30.5
EPS (TTM)
-$0.07
52W Low $0.71High $2.53

Volume 2.02M

Average 2.48M

LXRX Operating Cash Flow

Cash generated by the company's core business operations during the period.

Lexicon Pharmaceuticals, Inc.NASDAQ: LXRX

Operating Cash Flow · Q1 FY2026 · quarter ended Mar 2026

Operating cash flow declines year over year

Q1 FY2026 operating cash flow of $14.73M (cash outflow) fell 66.4% year over year, ahead of the -76.8% change in trailing-twelve-month operating cash flow. Sequentially, it fell 14.5% from the prior quarter. Over 3 fiscal years it compounded at -8.6% a year.

Context

  • Operating cash flow amounted to 136.2% of revenue in FY2025, down 439.0 pp from a year earlier.
  • Operating cash flow grew in size in 2 of the last 3 fiscal years.
  • FY2025 was the smallest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of -66.4% holds above the trailing-twelve-month pace of -76.8%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$14.73M-14.5% QoQ
Last fiscal yearDec 2025
-$67.85M-62.0% YoY
LTMMar 2026
-$38.8M-76.8% YoY
Operating Cash Flow past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-66.4%——
1 year-62.0%——
3-year CAGR-8.6%——
5-year CAGR——
10-year CAGR——

Operating Cash Flow history

USD · from the cash flow

Latest · FY2025
(67.85M) USD
Year-over-year change
+62.0%

Operating Cash Flow vs competitors

How LXRX compares with its peers on the latest reported figures

  • LXRX's LTM Mar 2026 operating cash flow of $38.8M is the 8th largest of the 11 companies compared; the peer median is $36.5M.
  • Its year-over-year change of -76.8% is the 10th highest of 11, against a peer median of +17.3%.
  • Operating cash flow amounts to 55.7% of revenue for LXRX, versus a peer median of 32.4%.
LXRX Competitors Peer median
Operating Cash Flow for LXRX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
IONSIonis Pharmaceuticals, Inc.LTM Sep 2026$544.41M +120.4%-0.7%56.7%
BCRXBioCryst Pharmaceuticals, Inc.LTM Jun 2026$359.87M +2039.9%—38.3%
NMRANeumora Therapeutics, Inc. Common StockLTM Mar 2026$193.4M -3.0%+21.6%—
ORICORIC Pharmaceuticals, Inc.LTM Mar 2026$110.88M -3.8%+14.7%—
RIGLRigel Pharmaceuticals, Inc.LTM Mar 2026$79.27M +122.7%—26.4%
TRVITrevi Therapeutics, Inc.LTM Sep 2026$61.44M +39.6%+14.3%—
OVIDOvid Therapeutics Inc.LTM Mar 2026$41.95M -15.3%-11.5%589.1%
LXRXLexicon Pharmaceuticals, Inc.LTM Mar 2026$38.8M -76.8%-8.6%55.7%
DMACDiaMedica Therapeutics Inc.LTM Mar 2026$31.05M +37.6%+36.2%—
PTCTPTC Therapeutics, Inc.LTM Jun 2026$30.5M -104.3%—3.0%
MNKDMannKind CorporationLTM Mar 2026$18.83M -36.0%—5.2%
Peer median (excluding LXRX) $36.5M+17.3%+14.5%32.4%

Competitors are the stored peer set for LXRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(87.76M)(101.94M)(177.12M)(200.4M)(50.34M)
Depreciation & Amortization292K427K554K534K621K
Deferred Income Tax49K0000
Stock-Based Compensation10.58M11.52M14.34M13.5M12.52M
Change in Working Capital(10.23M)402K2.66M14.24M(26.89M)
Accounts Receivables381K(14K)(982K)(2.46M)1.09M
Inventory00(381K)150K(50K)
Accounts Payables(14.16M)76K6.45M14.8M(30.22M)
Other Working Capital3.55M340K(2.43M)1.75M2.29M
Other Non-Cash Items54K744K(2.33M)(6.65M)(3.75M)
Operating Cash Flow(87.02M)(88.85M)(161.9M)(178.78M)(67.85M)
Capital Expenditures(1.22M)(1.33M)(470K)(1.03M)0
Acquisitions (Net)(3.33M)69.75M000
Purchases of Investments(34.26M)(133.95M)(223.34M)(338.05M)(143.55M)
Sales of Investments37.59M64.2M173.87M314.4M252.86M
Other Investing Activities3.33M(69.75M)09.31M3.71M
Investing Cash Flow2.11M(71.08M)(49.94M)(15.38M)113.02M
Debt Repayment(11.7M)48.87M49.96M0(48M)
Common Stock Issued37.08M94.21M138.82M64K73K
Common Stock Repurchased(2.68M)(864K)(824K)(1.73M)0
Dividends Paid00000
Other Financing Activities094.21M0(1.24M)(572K)
Financing Cash Flow22.71M142.21M187.96M238.35M(48.5M)
Effect of Forex Changes00000
Net Change in Cash(62.2M)(17.72M)(23.88M)44.19M(3.33M)
Free Cash Flow(88.24M)(90.18M)(162.37M)(179.81M)(67.85M)

Lexicon Pharmaceuticals, Inc.

NASDAQ:LXRX

Intrinsic Alpha fair value

Locked

Current Price

$1.72

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.